AstraZeneca’s Fasenra receives expanded FDA approval to treat paediatric patients with severe asthma
AstraZeneca (AZ) has announced that its Fasenra (benralizumab) has received expanded approval from the US Food and Drug Administration (FDA) as an add-on maintenance treatment for paediatric patients aged six to 11 years with severe eosinophilic asthma ( …